(Natural News)—Chronic disease rates have skyrocketed, obesity is at an all-time high, and life expectancy is declining in the U.S. The root of the crisis? A symbiotic relationship between industrial agriculture and pharmaceutical industries that prioritizes profit over public health.
- Chronic disease rates in the U.S. have surged from 7.5% in the 1930s to 60% today, while obesity now affects 40% of Americans.
- Four corporations dominate agriculture, controlling 85% of beef packing, 70% of pork packing, and 95% of corn intellectual property.
- Pharmaceutical companies spent 294 million on lobbying in 2024, while agribusinesses spent 32.7 million, with Bayer leading the charge.
- Both industries thrive on dependency cycles: farmers rely on synthetic inputs, while patients depend on lifelong medications.
America is in the midst of a health crisis unlike any it has faced before. In the 1930s, chronic diseases affected just 7.5% of the population. Today, that number has ballooned to 60%, with obesity rates climbing to 40%. Even more alarming, the U.S. is the only developed nation where both healthy life expectancy and total life expectancy are declining — a trend that began before the COVID-19 pandemic. Despite advancements in technology and medicine, we are living shorter, sicker lives than our grandparents.
The root of this crisis lies in the intertwined systems of Big Ag and Big Pharma — two industries that profit from keeping us dependent on their products. From the food we eat to the medications we take, these corporations have created a cycle of dependency that undermines our health and the health of the planet.
Bayer: The poster child of Big Ag and Big Pharma
When it comes to the overlap between agriculture and pharmaceuticals, Bayer stands out as a prime example. The German multinational, which acquired Monsanto in 2018 for $63 billion, now operates across pharmaceuticals, consumer health, and agriculture. This merger created a corporate behemoth that wields significant influence over both what we eat and how we treat our illnesses.
Bayer’s pharmaceutical division produces blockbuster drugs like Xarelto for cardiovascular issues and Stivarga for cancer, while its consumer health division markets household names like Claritin and MiraLAX. Meanwhile, its agricultural arm, bolstered by Monsanto’s expertise, dominates the global seed and agrochemical markets.
But this consolidation of power raises serious questions. Can a corporation truly champion health while promoting agricultural practices that rely on synthetic fertilizers, pesticides, and genetically modified (GM) crops — practices that degrade soil health and contribute to chronic diseases?
The concentration of power in both industries is staggering. The CR4 metric, which measures the market share of the top four firms in an industry, reveals just how monopolized these sectors have become.
- Agriculture: The CR4 for beef packing has soared from 25% in 1977 to 85% in 2018. Similarly, four companies control 95% of U.S. corn intellectual property and 84% of soybean intellectual property.
- Pharmaceuticals: In the vaccine market, Pfizer, GSK, Sanofi, and Merck control nearly 80% of global sales. Diabetes drugs are dominated by Novo Nordisk, Eli Lilly, and Sanofi, with a CR4 of about 70%.
This concentration of power allows corporations to dictate prices, policies, and market access, often at the expense of consumers and small-scale farmers. Farmers are locked into systems that require them to purchase expensive inputs like GM seeds and synthetic fertilizers, while patients are funneled into lifelong medication regimens that treat symptoms rather than addressing root causes.
Government funding: reinforcing dependency
Both industries rely heavily on government subsidies and policies that perpetuate their profit-driven models. In agriculture, federal programs like the Crop Insurance Program incentivize high-yield, chemical-intensive farming, while sidelining regenerative practices like crop rotation and cover cropping.
Similarly, healthcare policies prioritize pharmaceutical treatments over preventive care. Insurance plans often cover medications and surgeries but exclude holistic approaches like nutrition counseling or alternative therapies. This creates a cycle of dependency that benefits corporations while leaving consumers and farmers trapped in unsustainable systems.
Lobbying further entrenches these industries’ power. In 2024, pharmaceutical companies spent 294 million on lobbying efforts, while agribusinesses spent 32.7 million. Bayer alone spent $6.46 million in the U.S., ensuring that policies and regulations align with their interests.
Gut health and soil health: A striking parallel
The connection between human health and agriculture becomes even clearer when examining the parallels between gut health and soil health. Just as a balanced gut microbiome is essential for overall health, a thriving soil microbiome is crucial for producing nutrient-dense food.
However, industrial agriculture’s reliance on synthetic inputs disrupts the soil microbiome, leading to pest invasions, nutrient deficiencies, and a dependence on even more chemicals. This mirrors the overuse of antibiotics, which disrupts the gut microbiome and can lead to chronic health issues.
By improving soil health through regenerative farming practices, we can break this cycle of dependency and produce food that truly nourishes us. Similarly, focusing on preventive healthcare — through diet, exercise, and stress management — can reduce our reliance on pharmaceuticals.
The systems we rely on for food and healthcare are broken. Big Ag and Big Pharma have created a world where dependency is profitable, and health is secondary. But real change won’t come from the top down; it will come from the bottom up.
By supporting regenerative agriculture and choosing food produced without harmful chemicals, we can drive a market shift toward sustainability. Likewise, by taking control of our health and focusing on prevention, we can reduce our dependence on pharmaceuticals. The choice is ours: continue down a path of dependency and declining health, or invest in a future where health and sustainability take priority over corporate profits.
Sources include:
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.